Collegium Pharmaceutical, Inc. logo COLL - Collegium Pharmaceutical, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 3
SELL 1
STRONG
SELL 0
| PRICE TARGET: $58.00 DETAILS
HIGH: $60.00
LOW: $56.00
MEDIAN: $58.00
CONSENSUS: $58.00
UPSIDE: 70.24%

Stock News

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio - - Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 - - Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition - - 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million - STOUGHTON, Mass.

May 12, 2026 03:31 AM • globenewswire.com
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year –  – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

May 07, 2026 03:30 AM • globenewswire.com
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference

Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference

Collegium Pharmaceutical (NASDAQ: COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham and Company's 25th Annual Healthcare Conference. President and CEO Vikram Karnani and Chief Financial Officer Colleen Tupper spoke with Needham healthcare analyst Serge Belanger about growth drivers across the company's ADHD and

Apr 16, 2026 11:31 PM • defenseworld.net
Head to Head Contrast: Collegium Pharmaceutical (NASDAQ:COLL) versus electroCore (NASDAQ:ECOR)

Head to Head Contrast: Collegium Pharmaceutical (NASDAQ:COLL) versus electroCore (NASDAQ:ECOR)

electroCore (NASDAQ: ECOR - Get Free Report) and Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Volatility and Risk electroCore has a beta of

Mar 28, 2026 10:29 PM • defenseworld.net
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Collegium Pharmaceutical (NASDAQ: COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second commercial-stage ADHD product alongside Jornay PM and extend the durability of its ADHD revenue base. Transaction terms and timing On the investor call, President and CEO Vikram Karnani

Mar 20, 2026 09:02 PM • defenseworld.net
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to Generate Over $50 Million in Second Half 2026 Pro Forma Net Revenue – – Expected Patent Protection into 2037 – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition to Be Funded by Collegium's Cash on Hand and Previously Announced $300 Million Delayed Draw Term Loan – – Conference Call Scheduled for Today at 9:00 a.m. ET – STOUGHTON, Mass.

Mar 19, 2026 04:00 AM • globenewswire.com
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

Collegium Pharmaceutical (NASDAQ: COLL) highlighted a "record-breaking" 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD product JORNAY PM alongside what management described as a durable pain portfolio. Management recaps a record 2025 CEO Vikram Karnani said 2025 delivered record net revenues and record adjusted EBITDA, alongside

Mar 15, 2026 10:02 PM • defenseworld.net
Collegium to Present New Real-World Data at PainConnect 2026

Collegium to Present New Real-World Data at PainConnect 2026

STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium's pain portfolio and reflect the Company's continued focus on generating evidence that helps inform everyday practice.

Mar 05, 2026 03:00 AM • globenewswire.com
Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Monday, March 9, 2026Miami, FL Jefferies Biotech on the Beach Summit Tuesday, March 10, 2026Miami, FL The Citizens Life Sciences Conference Tuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare Conference Fireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m.

Mar 02, 2026 03:00 AM • globenewswire.com

Price Targets